‘Universal’ Cancer Vaccine Shows Stunning Results In Mice And Dogs

GAINESVILLE, Fla. — Cancer researchers have developed what they describe as a potential universal cancer vaccine — a groundbreaking RNA-based treatment that helps “wake up” unresponsive, or “cold,” tumors and make them vulnerable to immunotherapy drugs. Unlike traditional cancer vaccines that target specific tumor mutations, this new strategy uses broadly applicable immune activators that could eventually transform treatment for many patients whose cancers currently don’t respond to existing therapies.

Published in Nature Biomedical Engineering, the study reveals that the vaccine works by jump-starting the body’s early interferon response — a critical immune alarm system that alerts immune cells to danger. When this system fails to activate properly, tumors can grow unchecked, even in the presence of immune checkpoint inhibitors (ICIs), which are otherwise powerful immunotherapy drugs.

According to a University of Florida press release, the researchers believe this strategy could eliminate the need to tailor a vaccine to individual cancer types, opening the door to more standardized, broadly effective treatments.

“This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus — so long as it is an mRNA vaccine — could lead to tumor-specific effects,” said senior author Dr. Elias Sayour, a UF Health pediatric oncologist, in a statement.

How Scientists Identified the Missing Link in Cancer Treatment

The research team focused on type-I interferons, signaling molecules that act as the immune system’s first line of defense. These molecules function like emergency broadcast signals, telling surrounding cells to prepare for an attack. In theory, tumors should trigger this signal, but many cancers evolve to suppress or avoid it entirely.

Using multiple mouse models that mirror human cancer behavior, including brain tumors, melanoma, and osteosarcoma, the researchers made a striking discovery: when the interferon system was blocked, the benefits of immunotherapy were lost entirely. Mice with otherwise responsive tumors stopped benefiting from checkpoint inhibitors when their interferon signaling was disrupted.

In a second experiment, researchers transferred immune cells from mice that had responded well to immunotherapy into mice with resistant tumors. The treatment worked, but only if the recipient’s interferon system was still functioning, underscoring the central role of this pathway in driving anti-tumor immune responses.

RNA Vaccine Strategy Shows Promise in Resistant Cancers

Rather than stopping at discovery, the team developed a potential solution. They created RNA vaccines using lipid nanoparticles, similar to those used in COVID-19 vaccines. But instead of targeting tumor-specific proteins, these vaccines encoded proteins known to activate the interferon system, such as GFP, luciferase, and CMV pp65.

The approach proved highly effective across multiple cancer models. In studies involving mice with aggressive brain tumors, melanomas, and lung metastases, the RNA vaccines helped transform non-responsive tumors into ones that could be treated successfully with immunotherapy.

Perhaps most notably, the vaccines also worked as standalone treatments. Mice that received only the RNA vaccine (without additional immunotherapy drugs) showed significantly improved survival. Some achieved complete tumor clearance and resisted cancer recurrence when re-challenged with the same type of tumor weeks later.

The researchers say this kind of broadly effective approach could help expand immunotherapy access for many patients, regardless of cancer type.

Immune System Launches Broader Attack Against Cancer

One of the most intriguing effects observed was a process known as “epitope spreading.” The RNA vaccines were originally designed to target non-tumor antigens, but they appeared to spark a broader immune response. Over time, the immune system began recognizing tumor-associated proteins as well, effectively expanding its attack.

The study reported that vaccinated mice developed immune responses that extended beyond the artificial antigens encoded by the vaccine. The researchers observed that this broadened immune response helped drive sustained tumor control.

To test the vaccine’s broader relevance, the team used it in immunocompromised mice implanted with human osteosarcoma tumor cells. The vaccine still showed anti-tumor activity. They also conducted preliminary safety tests in three pet dogs with naturally occurring brain tumors and found no significant side effects from a single dose.

Toward an Off-the-Shelf Cancer Immunotherapy

Patients with tumors that have low mutation burdens — meaning fewer abnormal proteins to target—often don’t respond well to current immunotherapy approaches. These include many common cancers and represent a large unmet medical need.

The researchers believe their method could serve as a platform for developing broadly applicable cancer vaccines. As noted in the press release, this discovery lays the groundwork for a potential class of “universal” vaccines that don’t need to be customized to each individual tumor.

Rather than developing personalized vaccines tailored to an individual’s tumor mutations, the new method uses standardized immune activators that could be manufactured and administered more broadly, reducing cost and accelerating treatment timelines.

“This finding is a proof of concept that these vaccines potentially could be commercialized as universal cancer vaccines to sensitize the immune system against a patient’s individual tumor,” said Sayour, who is the principal investigator at the RNA Engineering Laboratory within UF’s Preston A. Wells Jr. Center for Brain Tumor Therapy.

Still, several hurdles remain before human trials can begin. The researchers used unmodified RNA, which contains natural uridines and stimulates stronger innate immune responses than the modified RNA used in existing mRNA vaccines. Determining the safest dosing schedules, identifying the most responsive cancer types, and completing larger animal studies will all be necessary next steps.

While still in the preclinical phase, the study provides a strong foundation for what may become a new class of off-the-shelf cancer vaccines.

Disclaimer: This report is based on preclinical findings from laboratory animal studies and limited safety tests in dogs. The vaccine has not yet been tested in humans. While the results are promising, further research and clinical trials are required to determine safety and effectiveness in people. Readers should not interpret this as a confirmed or available cancer treatment.

---